Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Chronic Hepatitis C Who Have Not Achieved an Undetectable HCV RNA Level With Previous Interferon Based Therapy
A Phase 3 Study of MP-424 in Combination With Peginterferon Alfa-2b and Ribavirin (RBV) in Subjects With (Genotype 1) Hepatitis C Who Did Not Respond to Previous Treatment
Sponsor: Tanabe Pharma Corporation
Listed as NCT00781274, this PHASE3 trial focuses on Hepatitis C and remains completed. Sponsored by Tanabe Pharma Corporation, it has been updated 8 times since 2008, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
8 versions recorded-
Feb 2026 — Present [monthly]
Completed PHASE3
-
Jan 2026 — Feb 2026 [monthly]
Completed PHASE3
-
Sep 2025 — Jan 2026 [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
▶ Show 3 earlier versions
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE3
First recorded
Dec 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Tanabe Pharma Corporation
- Vertex Pharmaceuticals Incorporated
For direct contact, visit the study record on ClinicalTrials.gov .